Genzyme would like to provide an update to the US Pompe community regarding the transition to commercial LumizymeTM (alglucosidase alfa) from the ATAP (Alglucosidase Alfa Temporary Access Program) in the United States. As a reminder, Lumizyme was approved by the US Food and Drug Administration (FDA) on May 24, 2010. Please visit for important safety information about Lumizyme including boxed warning for risk of anaphylaxis, severe allergic reactions, and immune-mediated reactions.

Download complete article